MA28064A1 - Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases - Google Patents

Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases

Info

Publication number
MA28064A1
MA28064A1 MA28721A MA28721A MA28064A1 MA 28064 A1 MA28064 A1 MA 28064A1 MA 28721 A MA28721 A MA 28721A MA 28721 A MA28721 A MA 28721A MA 28064 A1 MA28064 A1 MA 28064A1
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrazole derivatives
kinase inhibitors
derivatives active
active
Prior art date
Application number
MA28721A
Other languages
English (en)
Inventor
Daniele Fancelli
Barbara Forte
Jurgen Moll
Mario Varasi
Paola Vianello
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MA28064A1 publication Critical patent/MA28064A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Dérivés de pyrrolo[3,4-c]pyrazole actifs comme inhibiteurs de kinases Des dérivés de pyrrolo[3,4-c]pyrazole de formule (1) et leurs sels pharmaceutiquement acceptables, tels que définis dans le présent mémoire, un procédé pour leur préparation et des compositions pharmaceutiques les contenant sont décrits; les composés de la présente invention peuvent être utiles, en thérapeutique, dans le traitement de maladies associées à une dérégulation d'activité de protéine-kinases, telles que le cancer.
MA28721A 2003-07-09 2006-01-09 Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases MA28064A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09

Publications (1)

Publication Number Publication Date
MA28064A1 true MA28064A1 (fr) 2006-08-01

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28721A MA28064A1 (fr) 2003-07-09 2006-01-09 Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases

Country Status (42)

Country Link
US (2) US7141568B2 (fr)
EP (1) EP1644376B1 (fr)
JP (1) JP4728232B2 (fr)
KR (1) KR101075711B1 (fr)
CN (1) CN100564380C (fr)
AP (1) AP2214A (fr)
AR (1) AR050045A1 (fr)
AT (1) ATE480540T1 (fr)
AU (1) AU2004255347B2 (fr)
BR (1) BRPI0411868B8 (fr)
CA (1) CA2531759C (fr)
CR (1) CR8171A (fr)
CY (1) CY1110832T1 (fr)
DE (1) DE602004029045D1 (fr)
DK (1) DK1644376T3 (fr)
DO (1) DOP2004000949A (fr)
EA (1) EA009462B1 (fr)
EC (1) ECSP056246A (fr)
ES (1) ES2349780T3 (fr)
GE (1) GEP20084395B (fr)
GT (2) GT200400133A (fr)
HK (1) HK1089769A1 (fr)
HN (1) HN2004000232A (fr)
IL (1) IL172923A (fr)
IS (1) IS2843B (fr)
MA (1) MA28064A1 (fr)
ME (1) MEP51908A (fr)
MX (1) MXPA06000362A (fr)
MY (1) MY139072A (fr)
NO (1) NO332361B1 (fr)
NZ (1) NZ544514A (fr)
PA (1) PA8606201A1 (fr)
PE (1) PE20050325A1 (fr)
PL (1) PL1644376T3 (fr)
PT (1) PT1644376E (fr)
RS (2) RS52155B (fr)
SI (1) SI1644376T1 (fr)
TN (1) TNSN06009A1 (fr)
TW (1) TWI343382B (fr)
UA (1) UA81682C2 (fr)
WO (1) WO2005005427A1 (fr)
ZA (1) ZA200600095B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (fr) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles actifs en tant qu'inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les contenant
WO2005030776A1 (fr) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Derives de pyrazolopyrrole utilises en tant qu'inhibiteurs de proteines kinases
WO2005061519A1 (fr) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Inhibiteurs de kinase
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
JP2008510734A (ja) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) * 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (fr) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Dérivés de lactame bicycliques, leur fabrication et utilisation en tant qu'agents pharmaceutiques
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008052931A1 (fr) * 2006-11-03 2008-05-08 Nerviano Medical Sciences S.R.L. Procédé d'administration d'un composé anti-tumeur
AR071780A1 (es) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
US20110129467A1 (en) * 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
CN102105147B (zh) * 2008-07-24 2013-07-03 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
US20100183601A1 (en) 2008-12-22 2010-07-22 Millennium Pharmaceuticals, Inc. Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
CA2858958C (fr) 2011-12-12 2016-10-04 Dr. Reddy's Laboratories Ltd. Pyrazolo[1,5-a]pyridines substituees en tant qu'inhibiteurs du recepteur kinase lie a la tropomyosine (trk)
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US9394305B2 (en) 2014-06-23 2016-07-19 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
AU2016281225B2 (en) 2015-06-15 2020-10-15 Ube Corporation Substituted dihydropyrrolopyrazole derivative
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
WO2019195658A1 (fr) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Niveaux sting comme biomarqueur pour l'immunothérapie du cancer
WO2021041532A1 (fr) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Utilisation d'héparine pour favoriser la signalisation de l'interféron de type 1
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (fr) 2022-04-07 2023-10-12 Eli Lilly And Company Procédé de fabrication d'un inhibiteur de kras g12c
WO2023196887A1 (fr) 2022-04-08 2023-10-12 Eli Lilly And Company Méthode de traitement comprenant des inhibiteurs de kras g12c et des inhibiteurs d'aurora a
WO2024006424A1 (fr) 2022-06-30 2024-01-04 Eli Lilly And Company Inhibiteur de kras g12c pour le traitement du cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
CA2416527C (fr) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles actifs en tant qu'inhibiteurs de kinase, leur procede de preparation et compositions pharmaceutiques les contenant
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
CA2430151A1 (fr) 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Derives phenylacetamido-pyrazole et leur utilisation comme agents antitumoraux
EP1379524A2 (fr) 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Derives de chromane, procede de preparation et d'utilisation de ces derives en tant qu'agents antitumoraux
EA007430B1 (ru) 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
MEP51908A (en) 2011-05-10
CN100564380C (zh) 2009-12-02
SI1644376T1 (sl) 2010-11-30
CR8171A (es) 2006-08-09
EA009462B1 (ru) 2007-12-28
GT200400133AA (es) 2007-07-10
HK1089769A1 (en) 2006-12-08
IS8192A (is) 2005-12-22
ZA200600095B (en) 2007-01-31
BRPI0411868B8 (pt) 2021-05-25
AP2214A (en) 2011-03-04
ES2349780T3 (es) 2011-01-11
KR101075711B1 (ko) 2011-10-21
CA2531759A1 (fr) 2005-01-20
IS2843B (is) 2013-08-15
US20060276471A1 (en) 2006-12-07
ECSP056246A (es) 2006-04-19
MY139072A (en) 2009-08-28
ATE480540T1 (de) 2010-09-15
NZ544514A (en) 2009-07-31
US20050032839A1 (en) 2005-02-10
EA200600209A1 (ru) 2006-06-30
AR050045A1 (es) 2006-09-27
RS52155B (en) 2012-08-31
JP4728232B2 (ja) 2011-07-20
KR20060033001A (ko) 2006-04-18
IL172923A (en) 2011-09-27
AP2006003480A0 (en) 2006-02-28
AU2004255347A1 (en) 2005-01-20
TNSN06009A1 (fr) 2007-10-03
TW200510385A (en) 2005-03-16
PT1644376E (pt) 2010-09-24
US7141568B2 (en) 2006-11-28
IL172923A0 (en) 2006-06-11
EP1644376A1 (fr) 2006-04-12
BRPI0411868A (pt) 2006-08-08
PA8606201A1 (es) 2005-08-04
PL1644376T3 (pl) 2011-03-31
GT200400133A (es) 2005-04-18
AU2004255347B2 (en) 2010-04-08
EP1644376B1 (fr) 2010-09-08
WO2005005427A1 (fr) 2005-01-20
UA81682C2 (en) 2008-01-25
PE20050325A1 (es) 2005-05-17
TWI343382B (en) 2011-06-11
GEP20084395B (en) 2008-06-10
RS20060004A (en) 2008-06-05
CN1820009A (zh) 2006-08-16
DE602004029045D1 (de) 2010-10-21
HN2004000232A (es) 2011-01-17
MXPA06000362A (es) 2006-03-28
CY1110832T1 (el) 2015-06-10
CA2531759C (fr) 2013-04-02
JP2009513525A (ja) 2009-04-02
DOP2004000949A (es) 2005-01-15
US7582628B2 (en) 2009-09-01
NO20060113L (no) 2006-04-05
DK1644376T3 (da) 2011-01-03
NO332361B1 (no) 2012-09-03
BRPI0411868B1 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA27711A1 (fr) Derives de pyrazolo [1,5-a] pyrimidine
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TNSN05250A1 (fr) Pyrimidinones substituees
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
US20090275586A1 (en) Heterocyclic inhibitors of pde4
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
SI1678166T1 (sl) Inhibitorji proteinske kinaze
BRPI0017548A2 (pt) Composto, e, processo para a preparação de um composto
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
TNSN00239A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA26868A1 (fr) Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
ZA200704914B (en) Use of Thiazolidinone derivatives as antiangiogenic agents
HUP0301032A2 (hu) Ciklin-dependens kinázok N-{5-[(5-alkil-2-oxazolil)-metil-tio]-2-tiazolil}-karboxamid inhibitorai, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények